|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
FY2020
12 months to Dec 31, 2020
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net income (loss) | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Depreciation and amortization | |||||
| Claims amortization expense | |||||
| Paid-in-kind interest | |||||
| Impairment of intangible assets | |||||
| Allowance for credit losses | |||||
| Change in fair value of warrant liability | |||||
| Change in fair value of derivatives | |||||
| Gain on sale of intangibles | |||||
| Gain on debt extinguishment | |||||
| Mark- to-market gain on liability payable in stock | |||||
| Share based compensation | |||||
| Deferred income taxes | |||||
| Mark-to-market gain on liability payable in stock | |||||
| Professional fees settled in shares | |||||
| Non-cash lease expense | |||||
| Change in operating assets and liabilities: | |||||
| Accounts receivable | |||||
| Prepaid expenses and other assets | |||||
| Commission payable | |||||
| Accounts payable and accrued liabilities | |||||
| Deferred service fee income | |||||
| Affiliate receivable | |||||
| Affiliate payable | |||||
| Accounts payable, commission payable and accrued liabilities | |||||
| Interest Payable | |||||
| Net cash used in operating activities | |||||
| Cash flows from investing activities: | |||||
| Purchases of property and equipment | |||||
| Purchases of intangible assets | |||||
| Proceeds from sale of intangible assets | |||||
| Net cash (used in) provided by investing activities | |||||
| Cash flows from financing activities: | |||||
| Proceeds from debt financing | |||||
| Deferred financing costs | |||||
| Debt issuance costs | |||||
| Payments on related party loan | |||||
| Proceeds on related party loan | |||||
| Proceeds from Business Combination | |||||
| Transaction costs incurred for the Business Combination | |||||
| Release of temporary equity | |||||
| Repayment of the Claims financing obligation | |||||
| Proceeds from the issuance of common stock | |||||
| Issuance of temporary equity | |||||
| Net cash provided by financing activities | |||||
| Net increase (decrease) in cash | |||||
| Cash at beginning of year | |||||
| Cash at end of period | |||||
| Supplemental cash flow information: | |||||
| Supplemental disclosure of non-cash investing and financing activities: | |||||
| Purchase of intangible asset in accrued expenses | |||||
| Transaction costs incurred included in accounts payable | |||||
| Sale of intangible assets | |||||
| Purchase of intangible asset financed by note payable | |||||
| Release of temporary equity | |||||
| Original issue discount | |||||
| Purchase of intangible asset through issuance of Class A common stock | |||||
| Issuance of shares in settlement of debt | |||||
| Payment of professional fees through issuance of Class A common stock | |||||
| Transaction costs incurred included in accounts payable and accrued liabilities | |||||
| Non-cash lease liabilities arising from obtaining right-of-use assets | |||||
| Payment of Cano Health payment in shares | |||||
| Warrant conversions on a cashless basis | |||||
| Cash paid during the period for: | |||||
| Interest | |||||
Loading...